Barclays PLC Terns Pharmaceuticals, Inc. Transaction History
Barclays PLC
- $436 Billion
- Q2 2025
A detailed history of Barclays PLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 244,637 shares of TERN stock, worth $1.98 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
244,637
Previous 244,637
-0.0%
Holding current value
$1.98 Million
Previous $912,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding TERN
# of Institutions
132Shares Held
84.2MCall Options Held
173KPut Options Held
89.5K-
Soleus Capital Management, L.P. Greenwich, CT8.17MShares$66.2 Million2.36% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.56MShares$61.3 Million1.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT7.5MShares$60.8 Million0.99% of portfolio
-
Morgan Stanley New York, NY7.25MShares$58.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA6.9MShares$55.9 Million5.45% of portfolio
About Terns Pharmaceuticals, Inc.
- Ticker TERN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,613,800
- Market Cap $305M
- Description
- Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...